Free Trial
NASDAQ:SILO

Silo Pharma 11/13/2023 Earnings Report

Silo Pharma logo
$1.07 +0.04 (+4.35%)
Closing price 04/17/2025 03:56 PM Eastern
Extended Trading
$1.06 -0.02 (-1.75%)
As of 04/17/2025 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Silo Pharma EPS Results

Actual EPS
-$0.21
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Silo Pharma Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Silo Pharma Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Silo Pharma's next earnings date is estimated for Monday, May 12, 2025, based on past reporting schedules.

Conference Call Resources

Silo Pharma Earnings Headlines

Silo Pharma announces first dosing in IND-enabling study for SPC-15
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Silo Pharma files provisional patent for SPC-15 combination
See More Silo Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Silo Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silo Pharma and other key companies, straight to your email.

About Silo Pharma

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma (NASDAQ:SILO) in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

View Silo Pharma Profile

More Earnings Resources from MarketBeat